KYTX
NASDAQKyverna Therapeutics Inc.
Price$7.71+0.22 (+2.94%)
01:45 PM07:45 PM
News · 26 weeks71-15%
2025-12-142026-06-07
Mix3990d
- SEC Filings18(46%)
- Insider12(31%)
- Other3(8%)
- Earnings3(8%)
- Leadership3(8%)
Latest news
25 items- PRKyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid ArthritisMajority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset Miv-cel continues to demonstrate a well-tolerated safety profile, consistent with observations from over 100 patients treated to date1 Data reinforce miv-cel's differentiated clinical profile and opportunity to change the treatment paradigm across a variety of autoimmune diseases EMERYVILLE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases,
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- INSIDERDirector Cohen Fred E was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERDirector Clark Ian T was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERDirector Seidenberg Beth C was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERExecutive Chairperson Shaw Christi covered exercise/tax liability with 4,194 shares, decreasing direct ownership by 6% to 66,741 units (SEC Form 4) to cover taxes4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERDirector Aktar Mert was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERSEC Form 3 filed by new insider Martini Gregory S.3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Martini Gregory S.4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Names Greg Martini as Chief Financial OfficerEMERYVILLE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Greg Martini as Chief Financial Officer (CFO), effective May 18, 2026. Mr. Martini succeeds Dr. Marc Grasso who will be consulting for the Company to ensure a seamless transition. With this appointment, Mr. Martini will lead Kyverna's financial strategy and operations, including corporate finance, capital allocation, and investor relations, as the Company advances miv-cel (mivocabtagene autoleucel, KYV-101) toward a potential first approval in stiff
- PRKyverna Therapeutics to Present at Upcoming Investor ConferencesEMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that company management will present at the following upcoming conferences: H.C. Wainwright 4th Annual Nasdaq BioConnect Conference Format: Fireside chat and investor meetingsDate: Tuesday, May 19th, 2026Time: 2:30 p.m. ET Jefferies Global Healthcare Conference Format: Corporate presentation and investor meetingsDate: Wednesday, June 3rd, 2026Time: 3:10 p.m. ET Live webcasts of the presentations may be accessed via the Investors section of the Kyverna we
- SECSEC Form 10-Q filed by Kyverna Therapeutics Inc.10-Q - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial ResultsPositive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated Miv-cel pivotal trial primary analysis results in SPS demonstrated robust, durable effect in indication with no approved therapies; launch preparations continue with appointment of Nadia Dac as Chief Commercial Officer Enrollment advances in Phase 3 trial in generalized myasthenia gravis (gMG), further derisked by Phase 2 longer-term follow-up data demonstrating durable efficacy out to one year EMERYVILLE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on
- INSIDERSEC Form 4 filed by Chief Commercial Officer Dac Nadia4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dac Nadia3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial OfficerEMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of veteran commercial leader Nadia Dac as Chief Commercial Officer, effective May 4. With more than 30 years of US and global commercial leadership in the biopharmaceutical industry, Ms. Dac has deep experience successfully executing new product launches and building high-performing commercial organizations, including those making the transition to commercial-stage for the first time. At Kyverna, she will lead commercial strategy and executio
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual MeetingSingle-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS Data underscore potential for miv-cel to become the first and only approved treatment for SPS, fundamentally changing the treatment paradigm for patients and caregivers Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive prima
- SECKyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
- PRKyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial Totality of efficacy and safety data reinforces miv-cel's differentiated and potential best-in-class profile for delivering durable, drug-free, disease-free remission with a single dose Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET EMERYVILLE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive longer-term follow-up data from the Phase 2 por
- SECSEC Form DEFA14A filed by Kyverna Therapeutics Inc.DEFA14A - Kyverna Therapeutics, Inc. (0001994702) (Filer)
KYTX FAQ
6 questionsWhere does KYTX stock trade?
Kyverna Therapeutics Inc. (KYTX) is listed on NASDAQ.What sector and industry is KYTX in?
Kyverna Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Kyverna Therapeutics Inc. go public?
Kyverna Therapeutics Inc. (KYTX) completed its IPO in 2024.What are analysts saying about KYTX?
Kyverna Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2025-08-20.What companies are similar to KYTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare KYTX side-by-side with any of them on Quantisnow.How can I track KYTX on Quantisnow?
Quantisnow aggregates Kyverna Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KYTX to receive live email and push alerts on every new disclosure.